These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32618599)

  • 21. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases.
    Khlaiphuengsin A; Kiatbumrung R; Payungporn S; Pinjaroen N; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(18):8377-82. PubMed ID: 26745088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
    Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.
    Salomao M; Remotti H; Vaughan R; Siegel AB; Lefkowitch JH; Moreira RK
    Hum Pathol; 2012 May; 43(5):737-46. PubMed ID: 22018903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
    Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
    Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of CD4
    Miao Y; Li Z; Feng J; Lei X; Shan J; Qian C; Li J
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.
    Alexander J; Torbenson M; Wu TT; Yeh MM
    J Gastroenterol Hepatol; 2013 May; 28(5):848-54. PubMed ID: 23302015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.
    Yang JD; Ahmed F; Mara KC; Addissie BD; Allen AM; Gores GJ; Roberts LR
    Hepatology; 2020 Mar; 71(3):907-916. PubMed ID: 31309602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
    Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
    J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
    Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
    Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
    Fujiwara N; Nakagawa H; Enooku K; Kudo Y; Hayata Y; Nakatsuka T; Tanaka Y; Tateishi R; Hikiba Y; Misumi K; Tanaka M; Hayashi A; Shibahara J; Fukayama M; Arita J; Hasegawa K; Hirschfield H; Hoshida Y; Hirata Y; Otsuka M; Tateishi K; Koike K
    Gut; 2018 Aug; 67(8):1493-1504. PubMed ID: 29437870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.
    Yamaoka K; Saitoh S; Kinowaki K; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Fukusato T; Kumada H
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101799. PubMed ID: 34500120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
    Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
    J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.